BCAL Accelerates Rollout of Avantect Early Detection Tests
Filed with ASX · · 2 pages · English
Summary by 6ix AI
BCAL Diagnostics Limited announces the acceleration of the national rollout of its Avantect pancreatic and ovarian early detection blood tests, now available through selected pathology collection centers in multiple states and nationally via a new agreement. The Avantect test is designed to support early cancer detection using advanced genomic analysis and machine learning, improving clinical outcomes by identifying cancers at earlier stages.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
BCAL Diagnostics Limited on 6ix
Earlier from BCAL Diagnostics
- Half Yearly Report and Accounts
- Shareholder Update
- Quarterly Activities/Appendix 4C Cash Flow Report
- BCAL Early Cancer Detection Tests Update
- BCAL Establishes $10m Convertible Note Facility Revised
Later from BCAL Diagnostics
- BCAL Appoints Anne-Louise Arnett as Chief Executive Officer
- BCAL Launches Early Detection Cancer Platform
- BCAL Develops New Blood Test for Breast Cancer Recurrence
- BCAL Secures Funding for FY2027
- BCAL to Acquire Shares in Genetic Signatures
Follow BCAL Diagnostics into a list and get an email when it puts out news.
Follow BCAL Diagnostics